W.H.O. Research Team, Chulalongkorn Hospital Medical School, Bangkok, Thailand
The contraceptive steroid, medroxyprogesterone acetate (MPA), which at a dose of 150 mg can be injected every 3 months, is being considered for more widespread use in family planning programmes of developing countries, e.g. Thailand. Since MPA, in contrast to the combined oestrogen-progestagen steroids, does not decrease but may actually increase milk secretion when administered to lactating women (Karim et al., 1971; Koetswang, Chiemprajert & Kochananda, 1972) it could be used more for contraception during lactation.
There is no information on the effects of MPA, when administered to the lactating rat, on the subsequent growth, sexual maturation and reproductive function of the young. MPA may be ingested through the milk, as has been demonstrated for the oestrogen-progestagen steroids (Laumas, Malkani & Laumas, 1971), and affect the release of the gonadotrophic hormones now known to be secreted very early after birth and
Reproduction is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
Sept 2018 onwards | Past Year | Past 30 Days | |
---|---|---|---|
Full Text Views | 206 | 95 | 4 |
PDF Downloads | 81 | 27 | 0 |